- Home
- HTT vs EDIT Comparison
HTT vs EDIT Comparison
Compare HTT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HTT
High Templar Tech Limited American depositary shares each representing one Class A ordinary share
Current Price
Company Overview
Basic Information| Metric | HTT | EDIT |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.5M | 368.6M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HTT | EDIT |
|---|---|---|
| Price | $1.72 | $2.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $6.10 |
| AVG Volume (30 Days) | 74.0K | ★ 2.0M |
| Earning Date | 11-23-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | $92,865.41 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.14 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $1.72 | $1.66 |
| 52 Week High | $3.99 | $3.94 |
Technical Indicators
Market Signals| Indicator | HTT | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 15.88 | 57.02 |
| Support Level | N/A | $2.69 |
| Resistance Level | $2.69 | $2.91 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 1.43 | 83.69 |
Price Performance
Historical ComparisonAbout HTT High Templar Tech Limited American depositary shares each representing one Class A ordinary share
High Templar Tech Ltd is an enabler of financial technology. High Templar is focusing on exploring business opportunities globally to satisfy clients' demand by leveraging its technology know-how and financial service capabilities. The company focus empowering financial institutions with its technological capabilities, helping them improve marketing and operational efficiency and efficiently connect their diverse financial products with online traffic.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.